Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Guru Sonpavde MD
Guru P. Sonpavde MD Advisory Board
Jeffrey Kirshner MD, FACP, FASCO
Jeffrey J. Kirshner MD, FACP, FASCO Advisory Board
Sara Tolaney MD, MPH
Sara M. Tolaney MD, MPH Advisory Board
See All Experts
story of the week
Published in Oncology and
1 other channel

Journal Scan / Research · August 01, 2019

Erdafitinib in Urothelial Carcinoma

The New England Journal of Medicine

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Paul Hampel MD

Guru Sonpavde MD

The New England Journal of Medicine
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
N. Engl. J. Med 2019 Jul 25;381(4)338-348, Y Loriot, A Necchi, SH Park, J Garcia-Donas, R Huddart, E Burgess, M Fleming, A Rezazadeh, B Mellado, S Varlamov, M Joshi, I Duran, ST Tagawa, Y Zakharia, B Zhong, K Stuyckens, A Santiago-Walker, P De Porre, A O'Hagan, A Avadhani, AO Siefker-Radtke

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated